Literature DB >> 15785843

Bone mineral density of Brazilian girls with juvenile dermatomyositis.

T C M de Castro1, M T R A Terreri, V L Szejnfeld, C Len, A S M da Fonseca, M O E Hilário.   

Abstract

We measured bone mineral density (BMD) in girls with juvenile dermatomyositis (JDM) considering multiple factors in order to determine if it could be used as a predictor of reduction in bone mass. A cross-sectional study of lumbar spine BMD (L2-L4) was conducted on 10 girls aged 7-16 years with JDM. A group of 20 age-matched healthy girls was used as control. Lumbar spine BMD was measured by dual-energy X-ray absorptiometry. Weight, height and pubertal Tanner stage were determined in all patients and controls. Duration of disease and mean daily and cumulative steroid doses were calculated for all patients on the basis of their medical charts. JDM activity was determined on the basis of the presence of muscle weakness, cutaneous vasculitis and/or elevation of serum concentration of one or more skeletal muscle enzymes. Seven patients demonstrated osteopenia or osteoporosis. Lumbar BMD was significantly lower in the JDM patients than the age-matched healthy control girls (0.712 vs 0.878, respectively; Student t-test, P = 0.041). No significant correlation between BMD and age, height, Tanner stage, disease duration, corticosteroid use, or disease activity was observed in JDM girls, but a correlation was observed between BMD and weight (Pearson's correlation coefficient, r = 0.802). Patients with JDM may be at risk for a significant reduction in BMD that might contribute to further skeletal fragility. Our results suggest that reduced bone mass in JDM may be related to other intrinsic mechanisms in addition to steroid treatment and some aspects of the disease itself may contribute to this condition.

Entities:  

Mesh:

Year:  2005        PMID: 15785843     DOI: 10.1590/s0100-879x2005000200020

Source DB:  PubMed          Journal:  Braz J Med Biol Res        ISSN: 0100-879X            Impact factor:   2.590


  8 in total

1.  Variable deficits of bone mineral despite chronic glucocorticoid therapy in pediatric patients with inflammatory diseases: a Glaser Pediatric Research Network study.

Authors:  Emily von Scheven; Catherine M Gordon; David Wypij; Marcia Wertz; Kerry T Gallagher; Laura Bachrach
Journal:  J Pediatr Endocrinol Metab       Date:  2006-06       Impact factor: 1.634

2.  Prevalent vertebral fractures among children initiating glucocorticoid therapy for the treatment of rheumatic disorders.

Authors:  A M Huber; I Gaboury; D A Cabral; B Lang; A Ni; D Stephure; S Taback; P Dent; J Ellsworth; C LeBlanc; C Saint-Cyr; R Scuccimarri; J Hay; B Lentle; M Matzinger; N Shenouda; D Moher; F Rauch; K Siminoski; L M Ward
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-04       Impact factor: 4.794

3.  Increased osteoporosis risk in dermatomyositis or polymyositis independent of the treatments: a population-based cohort study with propensity score.

Authors:  Cynthia Wei-Sheng Lee; Chih-Hsin Muo; Ji-An Liang; Fung-Chang Sung; Chung-Y Hsu; Chia-Hung Kao
Journal:  Endocrine       Date:  2015-10-01       Impact factor: 3.633

4.  High frequency of osteoporosis and fractures in women with dermatomyositis/polymyositis.

Authors:  Danieli Castro Oliveira de Andrade; Sonia Cristina de Magalhães Souza; Jozélio Freire de Carvalho; Liliam Takayama; Claudia Teresa Lobato Borges; José Mendes Aldrighi; Rosa Maria Rodrigues Pereira
Journal:  Rheumatol Int       Date:  2011-02-16       Impact factor: 2.631

Review 5.  Glucocorticoid-induced osteoporosis in rheumatic diseases.

Authors:  Rosa Maria Rodrigues Pereira; Jozélio Freire de Carvalho; Ernesto Canalis
Journal:  Clinics (Sao Paulo)       Date:  2010       Impact factor: 2.365

Review 6.  Pediatric DXA: clinical applications.

Authors:  Larry A Binkovitz; Paul Sparke; Maria J Henwood
Journal:  Pediatr Radiol       Date:  2007-04-13

7.  Bone mineral density and explanatory factors in children and adults with juvenile dermatomyositis at long term follow-up; a cross sectional study.

Authors:  Henriette Schermacher Marstein; Kristin Godang; Berit Flatø; Ivar Sjaastad; Jens Bollerslev; Helga Sanner
Journal:  Pediatr Rheumatol Online J       Date:  2021-04-26       Impact factor: 3.054

8.  Changes in total body fat and body mass index among children with juvenile dermatomyositis treated with high-dose glucocorticoids.

Authors:  Amer Khojah; Victoria Liu; Gabrielle Morgan; Richard M Shore; Lauren M Pachman
Journal:  Pediatr Rheumatol Online J       Date:  2021-08-10       Impact factor: 3.054

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.